Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: DTIL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36.33
1 Year Target Price $36.33
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.33M USD | Price to earnings Ratio - | 1Y Target Price 36.33 |
Price to earnings Ratio - | 1Y Target Price 36.33 | ||
Volume (30-day avg) 4 | Beta 1.71 | 52 Weeks Range 3.61 - 9.20 | Updated Date 10/18/2025 |
52 Weeks Range 3.61 - 9.20 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -121538.89% |
Management Effectiveness
Return on Assets (TTM) -41% | Return on Equity (TTM) -143.89% |
Valuation
Trailing PE - | Forward PE 11.78 | Enterprise Value 31088491 | Price to Sales(TTM) 64.5 |
Enterprise Value 31088491 | Price to Sales(TTM) 64.5 | ||
Enterprise Value to Revenue 24.65 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 11786991 | Shares Floating 10550771 |
Shares Outstanding 11786991 | Shares Floating 10550771 | ||
Percent Insiders 11.32 | Percent Institutions 44.22 |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences Inc. was founded in 2006. It's focused on developing genome editing technologies for various applications. A key milestone was the development of their ARCUS platform. They have evolved from basic research to clinical-stage development.
Core Business Areas
- In Vivo Gene Editing: Developing therapies that directly deliver gene editing machinery into the body to treat genetic diseases.
- Ex Vivo Cell Therapy: Engineering cells outside the body, such as T cells, with improved therapeutic capabilities, and then re-introducing them into the patient.
Leadership and Structure
Derek Jantz is the co-founder and Chief Scientific Officer. Michael Amoroso is the CEO. The structure is typical for a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- PBCAR0191: Allogeneic CAR-T cell therapy targeting CD19 for B-cell malignancies. Currently in clinical trials. Competitors include Gilead (Kite Pharma) and Novartis. Market share data is not yet available as it's pre-commercial.
- In vivo gene editing programs: Developing therapies for diseases such as hepatitis B. Competitors include companies like Editas Medicine and CRISPR Therapeutics. Market share is not yet available.
Market Dynamics
Industry Overview
The gene editing and cell therapy industry is rapidly growing, driven by advancements in technology and increasing investment in research and development. There is strong competition and high regulatory scrutiny.
Positioning
Precision BioSciences is positioned as an innovator in gene editing with its ARCUS platform. It aims to provide more precise and versatile gene editing capabilities compared to other technologies.
Total Addressable Market (TAM)
The TAM for gene editing is estimated to reach tens of billions of dollars within the next decade. Precision BioSciences aims to capture a significant portion of this market through its various therapeutic programs.
Upturn SWOT Analysis
Strengths
- ARCUS platform's potential for high precision
- Strong intellectual property portfolio
- Experienced leadership team
- Focus on unmet medical needs
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on collaborations
- Risk of clinical trial failure
Opportunities
- Expanding partnerships with pharmaceutical companies
- Advancing clinical programs to later stages
- Expanding the application of ARCUS to new disease targets
- Potential for regulatory approvals
Threats
- Competition from other gene editing companies
- Regulatory hurdles
- Manufacturing challenges
- Potential for adverse events in clinical trials
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
- NTLA
Competitive Landscape
Precision BioSciences' ARCUS platform is its key differentiator. The company faces competition from companies with CRISPR and other gene editing technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing research and development expenses and progress in clinical trials.
Future Projections: Future growth depends on the success of clinical programs and securing partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include progressing lead clinical candidates and expanding the pipeline through partnerships and internal research.
Summary
Precision BioSciences is a biotechnology company focusing on gene editing using its ARCUS platform. It faces strong competition, but its unique technology offers potential advantages. Clinical trial success and strategic partnerships are critical for its future growth. While holding promise, the company carries risks common to early-stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary depending on the source. Financial data and forward-looking statements are subject to change and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 102 | Website https://precisionbiosciences.com |
Full time employees 102 | Website https://precisionbiosciences.com | ||
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.